简体
简体中文
繁體中文

TCW转型500 ETF VOTE 深 沪

等待开盘 10-23 09:30:00 美东时间

89.9467

-1.202

-1.32%

华盛通华盛通
立即下载
  • 最 高90.41
  • 今 开90.28
  • 成交量 8223股
  • 最 低 89.7699
  • 昨 收 91.1484
  • 总市值 112.25万
  • 52周最高 92.19
  • 市盈率 静 --
  • 换手率 65.89%
  • 52周最低 73.4434
  • 委 比 76.30%
  • 总股本 1.25万
  • 历史最高 92.19
  • 量 比 0.37
  • 振 幅 0.70%
  • 历史最低 37.2329
  • 每 手 1
  • 风险率 5.01%

个股概要

财务分析

公司资料

相关新闻

分红派息

  • 分时图
  • 日k
  • 周k
  • 月k

相关新闻

更多
  • Ethan Allen Highlights Case for Its Five Highly Qualified Director Nominees in Shareholder Mailer

    Ethan Allen outlines five key reasons to vote for its director nominees, emphasizing its debt-free platform, sustainable growth strategy, and ongoing CEO transition. The company criticizes DGB's proposed plan, stating it fails to demonstrate superiority or justify board changes. Ethan Allen highlights its vertically integrated business, strong financials, and current growth initiatives, while questioning DGB's lack of validated financial assumpti...

    10-19 14:34

  • Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics

    Alaunos Therapeutics completes acquisition of Velaris Therapeutics and raises $350 million via private placement to advance PAH therapies. Velaris' pipeline includes ActRII-Fc ligand traps and anti-PDGF-B antibody targeting pulmonary vascular remodeling. The funding supports clinical proof-of-concept data for VLR199 by 2028 and expansion into secondary pulmonary hypertension.

    10-13 14:31

  • 人工智能分析师推荐 2026年6月30日最值得买入的三只ETF

    TipRanks平台的人工智能分析师将三只ETF评为“跑赢大盘(买入)”评级,三只产品分别为维特思Silvant增长机遇ETF(代码VGRO)、一号引擎Tra...

    07-01 03:27